OraSure rises after Bundibugyo Ebola test receives US FDA emergency use nod

OraSure Technologies

22/07/2026 12:04

** Shares of diagnostic test maker OraSure Technologies OSUR.O rise 4.2% to $3.96 premarket
** Co says it has received Emergency Use Authorization (EUA) from the U.S. FDA for its second-generation OraQuick Ebola 2.0 Rapid Antigen Test for use with whole blood in live patients
** The test can also be used in cadaveric oral fluid from individuals suspected to have had Ebola disease at the time of death
** It can detect all four Ebola viruses currently known to cause disease in humans: Bundibugyo, Zaire, Sudan, and Taï Forest, OSUR says 
** More than 2,000 Ebola cases and nearly 1000 deaths have been recorded in Congo, with the epidemic is caused by the Bundibugyo strain of the virus
** Up to last close, stock rose 57% YTD 

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))